|
How does PARI create value for pharmaceutical
partners, caregivers, physicians? PARI focuses
on a comprehensive approach to aerosol therapy programs:
- Increased compliance due to fast treatments, portability
- Goal=treatments < 3 minutes
- High drug payload
- Less drug needed in low volume formulations
- Potential to lower adverse events
- Targeted or systemic therapies
- Tight geometric standard deviation (GSD) of droplet distribution
- As needed, device can be optimized for the formulation and the disease
- High patient satisfaction
- No special breathing technique
- Key aspects of drug and device project can be performed at PARI with experienced teams
- Multi-disciplinary project teams consisting of experts in engineering and pharmaceutical sciences
- PARI knows the strengths of the device better than anyone. Knowledge leads to optimized drug + device
- Years of experience with novel formulation approaches for eFLow Technology devices.
- Current drugs can be re-invented or new aerosol therapies can increase value and competitive edge
- PARI is the Gold Standard in Clinical Trials for Nebulized Medications
- 200 studies/posters on development topics
- On-Time delivery of devices for Clinical Trials
- Supply Agreements ensure supply of devices and involve partner in modifications
- High reproducibility of the device
- PARI licenses eFlow Technology the above technology for specific drugs and indications to development partners. Same drug for same indication is protected under license.
|
